RECOMBITEK® 4 Lepto (LCGIP)

Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona

DETAILS

RECOMBITEK® 4 Lepto is a liquid suspension of Leptospira bacterins containing serovars Canicola, Grippotyphosa, Icterohaemorrhagiae, and Pomona (LCGIP). Safety and immunogenicity of this product have been demonstrated by vaccination and challenge studies in susceptible dogs.

INDICATIONS

This product has been shown to be effective for the vaccination of healthy dogs, 9 weeks of age and older, against Leptospira canicola, L. grippotyphosa, L. icterohaemorrhagiae, and L. pomona. The duration of immunity against L. grippotyphosa is at least 15 months. The duration for the remaining organisms has not been determined.1

DOSAGE & ADMINISTRATION

Aseptically administer 1 mL (1 dose) subcutaneously into healthy dogs. For primary vaccination, revaccinate with a second 1-mL dose 3 to 4 weeks later. Historically, annual revaccination with this product has been recommended. The need for annual booster vaccination has not been established for this product.

PRECAUTIONS

Precautions: In rare instances, administration of vaccines may cause lethargy, fever, and inflammatory or hypersensitivity types of reactions. Treatment may include antihistamines, anti-inflammatories, and/or epinephrine, as directed by a veterinarian. This product has not been tested in pregnant animals. In case of human exposure, contact a physician.

 

Store at 35-46ºF (2-8ºC). Do not freeze. Do not use chemicals to sterilize syringes and needles.

 

Do not mix with other products. 
For use in animals only. Sold to veterinarians only.

Image of leptospirosis

Benefits of the RECOMBITEK® 4 Lepto Vaccine1,2

In a blinded, randomized, placebo-controlled, and commingled (placebo and vaccinates) laboratory study, the RECOMBITEK 4 Lepto vaccine provided significant protection against both leptospirosis* and urinary shedding of the bacterium (leptospiruria).

 

Despite most vaccinates being commingled with control dogs actively shedding spirochetes in their urine, 100% of vaccinates were protected from leptospirosis* for serovars Canicola, Icterohaemorrhagiae, and Grippotyphosa, and 95% of the vaccinates were protected from leptospirosis* for serovar Pomona.

 

Leptospiruria was prevented in 100% of the serovar Canicola and Grippotyphosa vaccinates. Leptospiruria was prevented in 89% and 95% of the vaccinates for serovars Icterohaemorrhagiae and Pomona respectively.

 

*Leptospirosis was defined as having at least 1 positive urine sample for leptospiruria and a positive renal histopathology score; or, in the absence of renal pathology, multiple positive urine samples for leptospiruria–these criteria for leptospirosis definition were evaluated and approved by the United States Department of Agriculture prior to study onset.

Benefits of the RECOMBITEK® 4 Lepto Vaccine1,2

In a blinded, randomized, placebo-controlled, and commingled (placebo and vaccinates) laboratory study, the RECOMBITEK 4 Lepto vaccine provided significant protection against both leptospirosis* and urinary shedding of the bacterium (leptospiruria).

 

Despite most vaccinates being commingled with control dogs actively shedding spirochetes in their urine, 100% of vaccinates were protected from leptospirosis* for serovars Canicola, Icterohaemorrhagiae, and Grippotyphosa, and 95% of the vaccinates were protected from leptospirosis* for serovar Pomona.

 

Leptospiruria was prevented in 100% of the serovar Canicola and Grippotyphosa vaccinates. Leptospiruria was prevented in 89% and 95% of the vaccinates for serovars Icterohaemorrhagiae and Pomona respectively.

 

*Leptospirosis was defined as having at least 1 positive urine sample for leptospiruria and a positive renal histopathology score; or, in the absence of renal pathology, multiple positive urine samples for leptospiruria–these criteria for leptospirosis definition were evaluated and approved by the United States Department of Agriculture prior to study onset.

Image of leptospirosis
Diagram showing how the RECOMBITEK 4 Lepto vaccine removes undesirable soluble proteins

Vaccine Purification

The RECOMBITEK® 4 Lepto vaccine is purified using a unique filtration technology (UFT), removing undesirable soluble proteins. What remains are the valuable Leptospira serovars, which are the foundation of our pure, four-way protective leptospirosis vaccine.

Vaccine Purification

The RECOMBITEK® 4 Lepto vaccine is purified using a unique filtration technology (UFT), removing undesirable soluble proteins. What remains are the valuable Leptospira serovars, which are the foundation of our pure, four-way protective leptospirosis vaccine.

Diagram showing how the RECOMBITEK 4 Lepto vaccine removes undesirable soluble proteins

15-Month Duration of Immunity for Serovar Grippotyphosa3

In a blinded, randomized, placebo-controlled laboratory study, 47- to 73-day-old puppies were vaccinated with either RECOMBITEK 4 Lepto and RECOMBITEK® C4/CV (rDAPPC) (vaccinates) or RECOMBITEK C4/CV placebo, twice at 21-day intervals. Four hundred seventy days after the second vaccination, dogs were challenged with a dog-virulent Leptospira kirschneri serovar Grippotyphosa.

 

RECOMBITEK 4 Lepto vaccine provided significant protection compared to the placebo for leptospirosis* following L. kirschneri serovar Grippotyphosa challenge 15 months after the primary series of vaccinations.

 

RECOMBITEK 4 Lepto vaccine provided significant protection compared to the placebo against leptospirosis* following L. kirschneri serovar Grippotyphosa challenge 15 months after the primary series of vaccinations.

 

*Leptospirosis was defined as having at least 1 positive urine sample for leptospiruria and a positive renal histopathology score; or, in the absence of renal pathology, multiple positive urine samples for leptospiruria–these criteria for leptospirosis definition were evaluated and approved by the USDA prior to study onset.

Order Now

Log in to BI-CONNECT™ to place an order for RECOMBITEK 4 Lepto.

Order Now

Log in to your BI-CONNECT™ account or create a new account to place an order.

Bottles of Recombitek Vaccines

RECOMBITEK® Canine Vaccines

 

RECOMBITEK® vaccines are highly purified, making them a safe and effective option to help protect your canine patients from dangerous diseases.

Bottles of Recombitek Vaccines

RECOMBITEK® Canine Vaccines

 

RECOMBITEK® vaccines are highly purified, making them a safe and effective option to help protect your canine patients from dangerous diseases.

Bottles of IMRAB Vaccines

IMRAB® Rabies Vaccines

 

Veterinarians worldwide trust US market-leading IMRAB® vaccines for proven multi-species rabies protection.4

Bottles of IMRAB Vaccines

IMRAB® Rabies Vaccines

 

Veterinarians worldwide trust US market-leading IMRAB® vaccines for proven multi-species rabies protection.4

Bottles of PUREVAX vaccines

PUREVAX® Feline Vaccines

 

Adjuvants can present potential risks to feline patients.5,6,7 PUREVAX® feline vaccines have been designed to elicit a protective immune response without the addition of adjuvants.

Bottles of PUREVAX vaccines

PUREVAX® Feline Vaccines

 

Adjuvants can present potential risks to feline patients.5,6,7 PUREVAX® feline vaccines have been designed to elicit a protective immune response without the addition of adjuvants.

Bottles of Recombitek Vaccines

RECOMBITEK® Canine Vaccines

 

RECOMBITEK® vaccines are highly purified, making them a safe and effective option to help protect your canine patients from dangerous diseases.

Bottles of Recombitek Vaccines

RECOMBITEK® Canine Vaccines

 

RECOMBITEK® vaccines are highly purified, making them a safe and effective option to help protect your canine patients from dangerous diseases.

Bottles of IMRAB Vaccines

IMRAB® Rabies Vaccines

 

Veterinarians worldwide trust US market-leading IMRAB® vaccines for proven multi-species rabies protection.4

Bottles of IMRAB Vaccines

IMRAB® Rabies Vaccines

 

Veterinarians worldwide trust US market-leading IMRAB® vaccines for proven multi-species rabies protection.4

Bottles of PUREVAX vaccines

PUREVAX® Feline Vaccines

 

Adjuvants can present potential risks to feline patients.5,6,7 PUREVAX® feline vaccines have been designed to elicit a protective immune response without the addition of adjuvants.

Bottles of PUREVAX vaccines

PUREVAX® Feline Vaccines

 

Adjuvants can present potential risks to feline patients.5,6,7 PUREVAX® feline vaccines have been designed to elicit a protective immune response without the addition of adjuvants.

References
  1. RECOMBITEK® 4 Lepto Product Label.

  2. Data on file at Boehringer Ingelheim.

  3. Grosenbaugh DA, Pardo MC. Fifteen-month duration of immunity for the serovar Grippotyphosa fraction of a tetravalent canine leptospirosis vaccine. Vet Rec. 2018;182(23):665.

  4. Data on file at Boehringer Ingelheim.

  5. Greene CE, Schultz RD. Immunoprophylaxis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. St Louis, MO: Elsevier Saunders; 2012:1166-1169.

  6. McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol. 2018;141(2):463-472.

  7. Day MJ, Schoon H-A, Magnol J-P, et al. A kinetic study of histopathological changes in the subcutis of cats injected with non-adjuvanted and adjuvanted multi-component vaccines. Vaccine. 2007; 25:4073-4084.
Trademarks

RECOMBITEK® and IMRAB® are registered trademarks and BI-CONNECT™ is a trademark of Boehringer Ingelheim Animal Health USA Inc. PUREVAX® is a registered trademark of Boehringer Ingelheim Animal Health France, used under license. ©2023 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. 

US-PET-0234-2021-A-V2